NEWARK, Del.--(BUSINESS WIRE)--iBio, Inc. (NYSE AMEX: IBIO) today announced the engagement of CBR International Corporation (CBR) for strategic regulatory and clinical services to advance iBio’s Orphan Drug designated, plant-produced human alpha galactosidase A (“a-Gal A”) enzyme candidate for development as a therapeutic option for patients with Fabry disease.
